Clinical Trial Update: Phase II Study of Regorafenib as Maintenance Therapy [Phase 2]

View source ↗

Summary

Phase II study of regorafenib as maintenance therapy for metastatic soft tissue sarcoma has completed. The trial was sponsored by Centre Oscar Lambret.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft-tissue Sarcoma

Drugs mentioned

• Stivarga (regorafenib) (regorafenib)

Snippet

Sponsor: Centre Oscar Lambret | Conditions: Metastatic Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED